As cell and gene therapy leaders gathered in Maryland to discuss accelerating clinical trials in children, one “cutting edge” ...
Stocktwits on MSN
NTLA stock surges 35% overnight: Retail mood peaks ahead of first-ever phase 3 readout for gene-editing therapy
The Haelo Phase 3 trial marks the first late-stage test of an in-vivo CRISPR gene-editing treatment. ・Earlier mid-stage studies showed a 96% reduction in monthly attack rates, with 97% of patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results